Skip to main content
Premium Trial:

Request an Annual Quote

Agendia Licenses Genetic Profile for Tamoxifen Resistance from Erasmus Medical Center

NEW YORK (GenomeWeb News) - Agendia said today that it has signed a license agreement with the Erasmus University Medical Center in Rotterdam, the Netherlands, giving it exclusive rights to a genetic profile that predicts resistance to tamoxifen.
 
Agendia said it will validate the tamoxifen profile in collaboration with the Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital.
 
Once validated, the company intends to add the profile to its MammaPrint gene expression-based breast cancer recurrence test.
 
In addition to the license agreement, the three organizations have entered a research collaboration focused on "next-generation hormonal therapies for breast cancer," Agendia said.
 
Financial terms of the agreement were not disclosed.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.